Encorafenib is used in combination with binimetinib or cetuximab. Refer to the binimetinib and cetuximab prescribing information for additional risk information pertaining to those drugs. What are the side effects of encorafenib? Common side effects of encorafenib in combination with binimetinib or ...
The most common side effects of BRAFTOVI when taken in combination with cetuximab and mFOLFOX6 forcolorectal cancerinclude:numbness, tingling, or burning in your hands or feet (peripheral neuropathy), nausea, fatigue, rash, diarrhea, decreased appetite, vomiting, bleeding (hemorrhage), stomach-area...
4.27.5 Side effects Nausea, vomiting, diarrhea, constipation, loss of appetite, headache, anxiety, seizures, fainting, weakness, confusion, tiredness, heartburn, irregular heartbeat, shortness of breath, mouth sores, dizziness, cough, fever, chills, sore throat, nose bleeding, bone pain, muscle...
Teniposide The serum concentration of Teniposide can be decreased when it is combined with Encorafenib. Tenofovir alafenamide The serum concentration of Tenofovir alafenamide can be increased when it is combined with Encorafenib. Tenofovir disoproxil The excretion of Tenofovir disoproxil can be decreas...
Side effects Dosage information During pregnancy Drug class: multikinase inhibitors En español Patient resources Encorafenib drug information Encorafenib (Advanced Reading) Other brands Braftovi Professional resources Encorafenib monograph Other brands Braftovi Related treatment guides Colorectal Cancer Mela...
Array also noted that the Part 2 combination dose was well tolerated, with adverse events (AEs) consistent with the reported side effects for the combination in Part 1. Additional data from Part 2 will be presented at an upcoming medical meeting this year. In Part 1 of the study, the ...
Our case highlights the importance of dermatological surveillance in high-risk patients on targeted therapies, and of education of both oncologists and dermatologists about the cutaneous side-effects. Dysplastic naevi and melanoma have not yet been reported with encorafenib, but we encourage clinicians...
Functional effects of amino acid substitutions were predicted in silico by the Polyphen-2 software. The Polyphen-2-based predictions were classified as benign (scores 0.000–0.449), possibly damaging (scores 0.450–0.959) or probably damaging (scores 0.960–1.000). 2.13. Statistical analysis The ...
In part 1 (n= 577) [66], combining encorafenib with binimetinib significantly reduced the risk of death by 39% versus vemurafenib (two-sidedP< 0.0001). OS in the encorafenib plus binimetinib and encorafenib arms was not significantly different (HR 0.81, 95% CI 0.61–1.06, two-sidedP...